Patents by Inventor Linan Song
Linan Song has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11434264Abstract: Ultrasensitive and quantitative assays for detecting toxins of Clostridium difficile, which may involve digital ELISA, are provided. Also provided herein are differential detection assays that allow for distinguishing toxin B of highly virulent Clostridium difficile strains from toxin B of less virulent strains.Type: GrantFiled: February 12, 2016Date of Patent: September 6, 2022Assignees: Quanterix Corporation, Beth Israel Deaconess Medical Center, Inc.Inventors: Nira Pollock, Ciaran Kelly, David C. Duffy, Linan Song, Mingwei Zhao
-
Publication number: 20220229073Abstract: The present disclosure relates to immunoassays for NF-L performed on liquid samples derived from physiological fluids such as venous blood to detect the presence or absence of a physiological condition by quantifying one or a combination of NF-L determinations at concentrations indicative of the condition.Type: ApplicationFiled: April 9, 2019Publication date: July 21, 2022Applicant: QUANTERIX CORPORATIONInventors: Edward Kevin HRUSOVSKY, David WILSON, Dandan SHAN, Lei CHANG, Linan SONG, Andreas JEROMIN, Carmen Ioana TOBOS, Purvish Prahlad PATEL
-
Publication number: 20210102959Abstract: The present disclosure relates to immunoassays for NF-L, GFAP, UCH L1, and Tau performed on liquid samples derived from physiological fluids such as venous blood to detect the presence or absence of a physiological condition by quantifying one or a combination of NF-L, GFAP, UCH L1, and Tau at concentrations indicative of the condition.Type: ApplicationFiled: April 9, 2019Publication date: April 8, 2021Applicant: QUANTERIX CORPORATIONInventors: Edward Kevin HRUSOVSKY, David WILSON, Dandan SHAN, Lei CHANG, Linan SONG, Andreas JEROMIN, Carmen Ioana TOBOS, Purvish Prahlad PATEL
-
Publication number: 20210096140Abstract: The present disclosure relates to digital immunoassays performed on diluted samples obtained from dried blood spots, for example dried capillary blood samples, to detect the presence or absence of a physiological condition by quantifying one or a combination of biomarkers at concentrations indicative of the condition.Type: ApplicationFiled: April 9, 2019Publication date: April 1, 2021Applicant: QUANTERIX CORPORATIONInventors: Edward Kevin HRUSOVSKY, David WILSON, Dandan SHAN, Lei CHANG, Linan SONG, Andreas JEROMIN, Carmen Ioana TOBOS, Purvish Prahlad PATEL
-
Patent number: 10640814Abstract: Described herein are methods and systems for detecting DNA or RNA using single molecules array or other techniques. DNA or RNA from the sample may be fragmented and exposed to a first type of binding ligand and a second type of binding ligand that comprise nucleic acid sequences complimentary at least a portion of a sequence contained in the target DNA or RNA. At least a portion of the fragmented DNA or RNA associates with at least one of the first type of binding ligand and/or the second type of binding ligand, wherein the first type of binding ligand and second type of binding ligand comprises nucleic acid sequences complimentary to a different portions of a sequence contained in the DNA or RNA. A portion of the sample exposed to the binding ligands is analyzed to determine the number of fragmented DNA or RNA sequences.Type: GrantFiled: March 30, 2018Date of Patent: May 5, 2020Assignee: Quanterix CorporationInventors: David C. Duffy, Linan Song, Dandan Shan, Mingwei Zhao
-
Publication number: 20180363038Abstract: Described herein are methods and systems for detecting DNA or RNA using single molecules array or other techniques. DNA or RNA from the sample may be fragmented and exposed to a first type of binding ligand and a second type of binding ligand that comprise nucleic acid sequences complimentary at least a portion of a sequence contained in the target DNA or RNA. At least a portion of the fragmented DNA or RNA associates with at least one of the first type of binding ligand and/or the second type of binding ligand, wherein the first type of binding ligand and second type of binding ligand comprises nucleic acid sequences complimentary to a different portions of a sequence contained in the DNA or RNA. A portion of the sample exposed to the binding ligands is analyzed to determine the number of fragmented DNA or RNA sequences.Type: ApplicationFiled: March 30, 2018Publication date: December 20, 2018Applicant: Quanterix CorporationInventors: David C. Duffy, Linan Song, Dandan Shan, Mingwei Zhao
-
Patent number: 9932626Abstract: Described herein are methods and systems for detecting DNA or RNA using single molecules array or other techniques. DNA or RNA from the sample may be fragmented and exposed to a first type of binding ligand and a second type of binding ligand that comprise nucleic acid sequences complimentary at least a portion of a sequence contained in the target DNA or RNA. At least a portion of the fragmented DNA or RNA associates with at least one of the first type of binding ligand and/or the second type of binding ligand, wherein the first type of binding ligand and second type of binding ligand comprises nucleic acid sequences complimentary to a different portions of a sequence contained in the DNA or RNA. A portion of the sample exposed to the binding ligands is analyzed to determine the number of fragmented DNA or RNA sequences.Type: GrantFiled: January 15, 2014Date of Patent: April 3, 2018Assignee: Quanterix CorporationInventors: David C. Duffy, Linan Song, Dandan Shan, Mingwei Zhao
-
Publication number: 20180037614Abstract: Ultrasensitive and quantitative assays for detecting toxins of Clostridium difficile, which may involve digital ELISA, are provided. Also provided herein are differential detection assays that allow for distinguishing toxin B of highly virulent Clostridium difficile strains from toxin B of less virulent strains.Type: ApplicationFiled: February 12, 2016Publication date: February 8, 2018Applicants: Quanterix Corporation, Beth Israel Deaconess Medical Center, Inc.Inventors: Nira Pollock, Ciaran Kelly, David C. Duffy, Linan Song, Mingwei Zhao
-
Patent number: 9678068Abstract: Described herein are systems and methods for the detection of and/or determination of a measure of the concentration of analyte molecules or particles in a fluid sample. In some cases, the systems and methods employ techniques to reduce or limit the negative effects associated with non-specific binding events. Certain methods of the present invention involve associating the analyte molecules at least a first type of binding ligand and at least a second type of binding ligand, and spatially segregating the analyte molecules into a plurality of locations on a surface. The presence of an analyte molecule at or in a location may be determined by determining the presence of both the first type of binding ligand and the second type of binding ligand.Type: GrantFiled: March 24, 2010Date of Patent: June 13, 2017Assignee: Quanterix CorporationInventors: David C. Duffy, David M. Rissin, David R. Walt, Linan Song, Lei Chang
-
Publication number: 20150353997Abstract: Described herein are methods and systems for detecting DNA or RNA using single molecules array or other techniques. DNA or RNA from the sample may be fragmented and exposed to a first type of binding ligand and a second type of binding ligand that comprise nucleic acid sequences complimentary at least a portion of a sequence contained in the target DNA or RNA. At least a portion of the fragmented DNA or RNA associates with at least one of the first type of binding ligand and/or the second type of binding ligand, wherein the first type of binding ligand and second type of binding ligand comprises nucleic acid sequences complimentary to a different portions of a sequence contained in the DNA or RNA. A portion of the sample exposed to the binding ligands is analyzed to determine the number of fragmented DNA or RNA sequences.Type: ApplicationFiled: January 15, 2014Publication date: December 10, 2015Applicant: Quanterix CorporationInventors: David C. Duffy, Linan Song, Dandan Shan, Mingwei Zhao
-
Publication number: 20140094386Abstract: The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of beta-amyloid peptide in a patient sample containing or suspected of containing beta-amyloid peptide.Type: ApplicationFiled: April 12, 2012Publication date: April 3, 2014Inventors: David Wilson, Linan Song
-
Publication number: 20110212462Abstract: Described herein are systems and methods for the detection of and/or determination of a measure of the concentration of analyte molecules or particles in a fluid sample. In some cases, the systems and methods employ techniques to reduce or limit the negative effects associated with non-specific binding events. Certain methods of the present invention involve associating the analyte molecules at least a first type of binding ligand and at least a second type of binding ligand, and spatially segregating the analyte molecules into a plurality of locations on a surface. The presence of an analyte molecule at or in a location may be determined by determining the presence of both the first type of binding ligand and the second type of binding ligand.Type: ApplicationFiled: March 24, 2010Publication date: September 1, 2011Applicant: Quanterix CorporationInventors: David C. Duffy, David M. Rissin, David R. Walt, Linan Song, Lei Chang
-
Publication number: 20100075862Abstract: The present invention relates to methods, systems, and kits for detecting, quantifying and/or analyzing a fluid sample comprising molecules or particles at low concentration. In certain embodiments, the methods for detection and/or quantifying analyte molecules in a sample comprise capturing a plurality of analyte molecules on a substrate (e.g., an array comprising a plurality of reaction vessels). The substrate may then be exposed to additional reaction components such as at least one binding ligand. The substrate may additionally be exposed to a precursor labeling agent molecule, wherein the precursor labeling agent molecule, in some cases, is converted to a labeling agent molecule, which may be detected, either directly or indirectly, which determination may be related to the presence of and/or may be employed to quantify the analyte molecules.Type: ApplicationFiled: September 23, 2008Publication date: March 25, 2010Applicant: Quanterix CorporationInventors: David C. Duffy, David M. Rissin, Linan Song, David R. Walt
-
Publication number: 20070251824Abstract: The invention relates to methods for isolating an analyte of interest in a sample suspected of containing the analyte of interest using two-dimensional planar electrochromatography. The methods comprise treating at least a portion of the sample with a mobility modifier capable of modifying the mobility of the analyte of interest after the second dimension of planar electrochromatography. Kits and compositions are also disclosed.Type: ApplicationFiled: January 24, 2007Publication date: November 1, 2007Applicant: PerkinElmer LAS, Inc.Inventors: Wayne Patton, Linan Song, Nancy Wilker